Test-Time Unlearning via Sparse Autoencoder
Read the original on arXiv Machine Learning →The Flow has not summarised this story yet — read it at arXiv Machine Learning.
The Flow has not summarised this story yet — read it at arXiv Machine Learning.
arXiv:2605. 12765v3 Announce Type: replace Abstract: Large Language Models memorize vast amounts of training data, raising concerns regarding privacy, copyright infringement, and safety.
The paper introduces Dynamic DAE Guardrails (DSG), a method that uses Dynamic Sparse Autoencoders to perform precision unlearning in large language models. DSG leverages principled feature selection and a dynamic classifier to target activation-based unlearning, outperforming existing gradient‑based methods in terms of computational efficiency, stability, sequential unlearning, resistance to relearning attacks, data efficiency, and interpretability.
arXiv:2608.21606v1 Announce Type: new Abstract: Machine unlearning aims to remove the influence of targeted training data from a model while preserving its remaining capabilities, but evaluating whet...
arXiv:2606. 06320v1 Announce Type: new Abstract: Machine unlearning aims to remove targeted knowledge from a trained model while preserving its general capabilities.
arXiv:2604. 26866v2 Announce Type: replace-cross Abstract: Large language models (LLMs) acquire most of their factual knowledge during the pre-training stage, through next token prediction.
The paper introduces ADU, a fine‑grained training framework that unlearns sensitive information from large language models by decoupling contextual attention pathways instead of erasing tokens. ADU exploits the distinction between local and global attention heads to identify and suppress attention paths that retrieve persistent sensitive anchors, while preserving local‑attention structure and overall language modeling performance. Evaluation on the TOFU and WMDP benchmarks shows ADU achieves superior forget quality (0.93 on TOFU) and retains 92.9% of model utility compared to 81.9% for existing baselines, with fewer side effects in benign contexts.